LivaNova wins FDA approval for aura6000 in sleep apnea

CURRENT FULL VERSION: LivaNova’s aura6000 system has secured US FDA premarket approval, giving the company a new entry into the obstructive sleep apnea market and expanding the field of implantable alternatives for adults who can’t use or don’t benefit from standard treatment. FDA records show the PMA decision was made on March 18, 2026, covering use in adults with moderate to severe OSA, defined as an apnea-hypopnea index of 15 to 65, who have failed, do not tolerate, or are ineligible for therapies including PAP, oral appliances, or pharmacotherapy. (accessdata.fda.gov)

The approval is the culmination of a multiyear regulatory effort. LivaNova received FDA approval in 2021 to begin the OSPREY investigational study of aura6000 in adults with moderate to severe OSA, then reported in November 2024 that the randomized controlled trial had met its primary safety and efficacy endpoints. At that point, the company said median AHI fell 66.2% and median ODI fell 63.3% at six months in the stimulation arm, with no serious adverse device-related or procedure-related events reported through the primary endpoint visits. LivaNova completed its PMA submission in April 2025. (businesswire.com)

Twelve-month data helped reinforce the filing. In May 2025, LivaNova reported top-line OSPREY results showing a 65% responder rate among actively treated patients at 12 months, alongside median 68% reductions in both AHI and ODI. The company also said those results extended across harder-to-treat subgroups, including patients with severe OSA, elevated body mass index, and those at high risk of complete concentric collapse. (investor.livanova.com)

That complete concentric collapse point may be one of the most commercially important details. Trade publication Sleep Review reported in October 2025 that, unlike some competing US neurostimulation programs, LivaNova’s OSPREY trial did not exclude patients with complete concentric collapse and did not require drug-induced sleep endoscopy screening to filter them out. The publication noted that this design choice could broaden the eligible population and simplify the treatment pathway if regulators ultimately accepted the data, which now appears to have happened with the FDA approval. That inference should be treated cautiously until full labeling is reviewed in detail, but it helps explain why the approval is drawing attention beyond the headline itself. (sleepreviewmag.com)

LivaNova and study investigators had been framing the device as a meaningful alternative for patients who struggle with conventional therapy. In the company’s November 2024 release, CEO Vladimir Makatsaria said the findings supported targeted hypoglossal nerve stimulation as a compelling option in OSA, while lead investigator Dr. Atul Malhotra of UC San Diego highlighted the clinical impact seen after six months of therapy. Those comments came before approval, but they reflect the positioning LivaNova is likely to carry into launch: a surgically implanted therapy aimed at patients left behind by adherence problems and treatment intolerance. (investor.livanova.com)

The approval also fits into a broader FDA pattern for implantable neuromodulation. In a separate recent decision, Nia Therapeutics received FDA Breakthrough Device designation for its Smart Neurostimulation System for episodic memory loss in adults with prior moderate to severe traumatic brain injury and persistent memory deficits. According to the company summary, that system is a fully implantable, closed-loop platform that records neural activity from 60 channels across four brain regions and delivers targeted stimulation to the lateral temporal cortex. Nia said the technology improved recall by 19% in a sham-controlled study of neurosurgical patients with epilepsy and a history of TBI, while random stimulation showed no benefit, and that it plans to file an IDE application in 2026. While that program is in a different indication and at an earlier regulatory stage than aura6000, it adds context: FDA interest in sophisticated implantable neurotechnology is not limited to sleep medicine. (pharmashots.com)

Why it matters: For clinicians and industry watchers, aura6000’s approval adds competitive pressure in a category that has been defined by a relatively small number of device-based options. It also suggests the FDA was comfortable with evidence from a sham-controlled randomized trial rather than relying only on single-arm data. If the final labeling preserves the broader-access features suggested by the trial design, the device could influence how sleep specialists think about candidate selection, pre-implant workups, and conversations with pet parents who increasingly expect more personalized care pathways across human and animal health alike. For veterinary professionals specifically, the broader relevance is regulatory: neuromodulation platforms continue to gain traction, and the FDA’s handling of these devices can offer useful signals about evidentiary standards, post-market expectations, and commercialization strategy in adjacent medtech fields. The recent Nia Breakthrough designation reinforces that point by showing continued agency willingness to engage with implantable, closed-loop neurostimulation concepts in other neurologic uses as well. (accessdata.fda.gov)

What to watch: The next milestones are practical rather than regulatory: detailed labeling review, reimbursement and payer positioning, surgeon and sleep-center training, and the pace of US launch execution. FDA’s PMA page also lists a post-approval study requirement, so follow-up data will matter as LivaNova moves from trial results to real-world adoption. In the wider neuromodulation space, upcoming IDE activity from companies such as Nia will also be worth watching as FDA continues to shape expectations for next-generation implantable systems. (accessdata.fda.gov)